New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)
February 01, 2024 01:03 ET
|
F. Hoffmann-La Roche Ltd
Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision Up to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months...
Renewable Energy Group Statement on Proposed Renewable Volume Obligations
July 05, 2017 18:04 ET
|
Renewable Energy Group, Inc.
AMES, Iowa, July 05, 2017 (GLOBE NEWSWIRE) -- Renewable Energy Group, Inc. (NASDAQ:REGI) President and CEO Randy Howard issued the following statement regarding the Environmental Protection Agency’s...
Clearside Biomedical, Inc. to Present at the 2016 Wedbush PacGrow Healthcare Conference
August 10, 2016 07:00 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat...